<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840331</url>
  </required_header>
  <id_info>
    <org_study_id>Hypericin-PDT</org_study_id>
    <nct_id>NCT02840331</nct_id>
  </id_info>
  <brief_title>Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis</brief_title>
  <acronym>Hypericin-PDT</acronym>
  <official_title>Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study would examine by hypericin-supported Fluoreszenzlaparoskopy in terms of tumor size,&#xD;
      number and location of the combination of photodynamic diagnosis (PDD) and therapy (PDT) with&#xD;
      regard to the detection of peritoneal metastases of locally advanced gastric cancer at 50&#xD;
      adult patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypericin-PDT study is an examination of patients with gastric cancer. The peritoneal&#xD;
      carcinosis (PC) of the adult represents the final stage of an advanced tumor and was treated&#xD;
      in the past, usually by means of palliative chemotherapy. An improvement in survival for&#xD;
      patients with PC could be further improved through the use of maximum cytoreductive surgery&#xD;
      (CRS) can be achieved with radical removal of the entire tumor mass and the combination of&#xD;
      CRS and intraperitoneal hyperthermic chemotherapy (HIPEC) event-free survival and overall&#xD;
      survival. A cure of patients is achieved only in the rarest cases. An essential problem in&#xD;
      the treatment of peritoneal carcinomatosis is that can only be poorly differentiated from&#xD;
      surrounding tissue due to their location, the tumors often not well recognized because of&#xD;
      their size or. This results to differ (as scar tissue) for the surgeon the difficulty between&#xD;
      eigentlichem tumor tissue and surrounding tissue.&#xD;
&#xD;
      Through the use of innovative diagnostic and therapeutic options (for example, photodynamic&#xD;
      diagnosis (PDD) and therapy (PDT)) above mentioned problems can be improved. In photodynamic&#xD;
      diagnosis contrast between tumor and surrounding healthy tissue is improved by an interaction&#xD;
      of photodynamic active substance with light of a particular wavelength. The PDT is based on a&#xD;
      topical or systemic administration of a photosensitizer (here hypericin), which is irradiated&#xD;
      with light of a suitable wavelength and in the presence of oxygen oxygen radicals (with the&#xD;
      consequence of a direct cytotoxicity of the tumor cells leading) forms.&#xD;
&#xD;
      The study will be carried out in the Department of General, Visceral and Transplantation&#xD;
      Surgery Tübingen at 50 adult patients. The study proposed would examine by&#xD;
      hypericin-supported Fluoreszenzlaparoskopy in terms of tumor size, number and location of the&#xD;
      combination of photodynamic diagnosis (PDD) and therapy (PDT) with regard to the detection of&#xD;
      peritoneal metastases of locally advanced gastric cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peritoneal metastases in terms of tumor size [centimeter, cm]</measure>
    <time_frame>Day 1 (day of surgery)</time_frame>
    <description>Detection of peritoneal metastases of locally - advanced gastric cancer by hypericin - supported Fluoreszenzlaparoskopie in terms of tumor size [cm]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peritoneal metastases in terms of number [n]</measure>
    <time_frame>Day 1 (day of surgery)</time_frame>
    <description>Detection of peritoneal metastases of locally - advanced gastric cancer by hypericin - supported Fluoreszenzlaparoskopie in terms of number [n]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peritoneal metastases in terms of location</measure>
    <time_frame>Day 1 (day of surgery)</time_frame>
    <description>Detection of peritoneal metastases of locally - advanced gastric cancer by hypericin - supported Fluoreszenzlaparoskopie in terms of location [central, right upper, epigastrium, left upper, , left flank, left lower, pelvis, riht lower, right flank, upper jejunum, lower jejunum, upper ileum, lower illeum]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypericin level</measure>
    <time_frame>Day 1 (day of surgery)</time_frame>
    <description>Hypericin levels in the peritoneum and serum the day of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological evidence of apoptosis</measure>
    <time_frame>Day 1 (day of surgery)</time_frame>
    <description>Histological evidence of apoptosis in peritoneal metastasis after photodynamic therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>St. John's Wort &amp; PDD, PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>St. John's Wort 900 milligram once oral preoperative &amp; intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>St. John's Wort</intervention_name>
    <description>Single oral doses (900 milligram) 2-4 hours before laparoscopy</description>
    <arm_group_label>St. John's Wort &amp; PDD, PDT</arm_group_label>
    <other_name>Laif 900</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photodynamic diagnostic and therapy</intervention_name>
    <description>Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes</description>
    <arm_group_label>St. John's Wort &amp; PDD, PDT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  Computertomography - morphologically locally - advanced gastric cancer (Classification&#xD;
             of Malignant Tumours (TNM): size or direct extent of the primary tumor &gt; 3 or degree&#xD;
             of spread to regional lymph nodes positive) without distant metastases (except&#xD;
             peritoneum)&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the stomach&#xD;
&#xD;
          -  Karnofsky Index &gt; 70&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are considered inoperable because of a reduced general condition:&#xD;
&#xD;
               -  Congestive heart failure (New York Heart Association (NYHA) Functional&#xD;
                  Classification III / IV),&#xD;
&#xD;
               -  Severe coronary heart disease, non-treatable arrhythmia or non-adjustable&#xD;
                  hypertension,&#xD;
&#xD;
               -  Severe asthma suffering (Chronic obstructive pulmonary disease)&#xD;
&#xD;
          -  Distant metastases except peritoneum&#xD;
&#xD;
          -  Patients with a contraindication related to the present study&#xD;
&#xD;
          -  Allergy or intolerance to the study drug or a substance with chemical similarity to&#xD;
             the study medication.&#xD;
&#xD;
          -  Lack of capacity to consent&#xD;
&#xD;
          -  Participation in another interventional therapy studies at intervals of 30 days&#xD;
&#xD;
          -  Contraindication to taking the prescribed study medication the physician's discretion&#xD;
&#xD;
          -  Pregnancy/ Breastfeeding&#xD;
&#xD;
          -  Women in childbearing age who refuse:&#xD;
&#xD;
               -  Simultaneously apply two appropriate contraceptive measures or maintain a full&#xD;
                  hetero-sexual abstinence at least 28 days prior to the study and for at least 28&#xD;
                  days after administration of study medication&#xD;
&#xD;
               -  To stop breast-feeding during the study and through 6 months after the end of&#xD;
                  study&#xD;
&#xD;
          -  Men who refuse:&#xD;
&#xD;
             - To use a latex condom during any sexual contact with childbearing women during the&#xD;
             study and at least 28 days after completion of study, even if they are successful&#xD;
             vasectomy.&#xD;
&#xD;
          -  - Sperm donor to make up at least 28 days after completion of study.-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Beckert, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Department of General, Visceral and Transplant Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Beckert, Prof. Dr.</last_name>
    <phone>+49-(0)7071-29-81222</phone>
    <email>stefan.beckert@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alfred Königsrainer, Prof. Dr.</last_name>
    <phone>+49-(0)7071-29-81222</phone>
    <email>alfred.koenigsrainer@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Department of General, Visceral and Transplant Surgery</name>
      <address>
        <city>Tübingen</city>
        <state>Baden.Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Beckert, Prof. Dr.</last_name>
      <phone>+49-(0)7071-29-86619</phone>
      <email>stefan.beckert@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Alfred Königsrainer, Prof. Dr.</last_name>
      <phone>+49-(0)7071-29-86619</phone>
      <email>alfred.koenigsrainer@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Stefan Beckert</investigator_full_name>
    <investigator_title>Chief consultant</investigator_title>
  </responsible_party>
  <keyword>Gastric carcinoma</keyword>
  <keyword>Peritoneal carcinomatosis</keyword>
  <keyword>Photodynamic diagnosis</keyword>
  <keyword>Photodynamic therapy</keyword>
  <keyword>St. John's Wort</keyword>
  <keyword>Peritoneal metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

